18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot studyReport as inadecuate




18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study - Download this document for free, or read online. Document in PDF available to download.

European Journal of Nuclear Medicine and Molecular Imaging

, Volume 38, Issue 6, pp 1059–1063

First Online: 06 January 2011Received: 09 September 2010Accepted: 03 December 2010

Abstract

PurposeF-Fluorodeoxyglucose positron emission tomography FDG PET has been used to assess metabolic response several months after stereotactic body radiotherapy SBRT for early-stage non-small cell lung cancer. However, whether a metabolic response can be observed already during treatment and thus can be used to predict treatment outcome is undetermined.

MethodsTen medically inoperable patients with FDG PET-positive lung tumours were included. SBRT consisted of three fractions of 20 Gy delivered at the 80% isodose at days 1, 6 and 11. FDG PET was performed before, on day 6 immediately prior to administration of the second fraction of SBRT and 12 weeks after completion of SBRT. Tumour metabolism was assessed semi-quantitatively using the maximum standardized uptake value SUVmax and SUV70%.

ResultsAfter the first fraction, median SUVmax increased from 6.7 to 8.1 p = 0.07 and median SUV70% increased from 5.7 to 7.1 p = 0.05. At 12 weeks, both median SUVmax and median SUV70% decreased by 63% to 3.1 p = 0.008 and to 2.5 p = 0.008, respectively.

ConclusionSUV increased during treatment, possibly due to radiation-induced inflammation. Therefore, it is unlikely that F-FDG PET during SBRT will predict treatment success.

KeywordsSBRT Lung tumours Response monitoring FDG PET  Download fulltext PDF



Author: Erwin M. Wiegman - Jan Pruim - Jan F. Ubbels - Harry J. M. Groen - Johannes A. Langendijk - Joachim Widder

Source: https://link.springer.com/







Related documents